Christopher Griffiths, AAD VMX 2021: Guselkumab VOYAGE-1 Study
It was an absolute pleasure to speak with Prof. Christopher Griffiths (University of Manchester, Manchester, UK) about recent developments in the treatment of psoriasis including the VOYAGE study.
Questions
- Could you tell us about the aims and design of the VOYAGE 1 study? (00:10-01:14)
- What has the study taught us about the efficacy and safety of guselkumab in psoriasis? (01:14-02:25)
- There are other novel IL-17/23 antagonists currently in development e.g. bimekizumab and mirikizumab, based on clinical data to date, which are you most excited/optimistic about? (02:25-03:42)
Disclosures: Christopher Griffiths has the following disclosures: AbbVie – (AD Board, Grant Holder), Almirall (Advisor), Amgen (Advisor), BMS (Speaker, Grant Holder) , Boehringer Ingelheim (Ad Board / Advisor), Celgene – (Ad Board / Speaker) , Galderma – (AD Board, Grant Holder) , Janssen – (Speaker, Grant holder) , LEO Pharma (Grant Holder / Speaker) , Lilly – (Grant Holder / Ad Board) , MSD (Advisor), Novartis (Ad Board / Speaker / Ad Board), Pfizer – (Grant Holder, Speaker) , Sandoz (Grant Holder) and UCB Pharma – (AD Board)
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
